Provided by Tiger Fintech (Singapore) Pte. Ltd.

OptimizeRx Corporation

7.77
+0.62008.67%
Post-market: 7.800.0301+0.39%19:52 EDT
Volume:1.07M
Turnover:8.07M
Market Cap:143.13M
PE:-5.78
High:8.00
Open:7.10
Low:6.84
Close:7.15
Loading ...

Stephens Initiates Coverage on OptimizeRx With Equal Weight Rating, $5.50 Price Target

MT Newswires Live
·
20 Dec 2024

OptimizeRx initiated with an Equal Weight at Stephens

TIPRANKS
·
20 Dec 2024

Analysts Conflicted on These Healthcare Names: OptimizeRx (OPRX) and Universal Health (UHS)

TIPRANKS
·
17 Dec 2024

OptimizeRx to Participate in Upcoming Investor Conferences

GlobeNewswire
·
18 Nov 2024

OptimizeRx Price Target Cut to $16.00/Share From $20.00 by Roth MKM

Dow Jones
·
15 Nov 2024

OptimizeRx Is Maintained at Buy by Stifel

Dow Jones
·
14 Nov 2024

RBC Cuts Price Target on OptimizeRx to $7 From $14, Keeps Outperform Rating

MT Newswires Live
·
14 Nov 2024

OptimizeRx price target lowered to $5 from $11 at Barclays

TIPRANKS
·
14 Nov 2024

Barclays Sticks to Their Hold Rating for OptimizeRx (OPRX)

TIPRANKS
·
14 Nov 2024

Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (PTCT), Medtronic (MDT) and OptimizeRx (OPRX)

TIPRANKS
·
14 Nov 2024

OptimizeRx Corp (OPRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts ...

GuruFocus.com
·
14 Nov 2024

OptimizeRx Corp reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
14 Nov 2024

OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings Estimates

Zacks
·
14 Nov 2024

OptimizeRx Q3 2024 Adj. EPS $0.12 Beats $0.06 Estimate, Sales $21.309M Miss $24.997M Estimate

Benzinga
·
14 Nov 2024

OptimizeRx Outlook FY24 Revenue to Be Between $88 Mln and $92 Mln

THOMSON REUTERS
·
14 Nov 2024

OptimizeRx Corp FY2024 REV View $100.7 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
14 Nov 2024